Koers VG Life Sciences Inc. Other OTC
Aandelen
VGLS
US91822T1016
Biotechnologie & Medisch Onderzoek
Omzet 2013 | - | Omzet 2014 | - | Marktkapitalisatie | 2,23 mln. 2,05 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2013 | -7 mln. -6,44 mln. | Nettowinst (verlies) 2014 | -6 mln. -5,52 mln. | EV/omzet 2013 | - |
Nettoschuld 2013 | 2,49 mln. 2,3 mln. | Nettoschuld 2014 | 3,83 mln. 3,52 mln. | EV/omzet 2014 | - |
K/w-verhouding 2013 |
-0,25
x | K/w-verhouding 2014 |
-0,31
x | Werknemers | - |
Dividendrendement 2013 * |
-
| Dividendrendement 2014 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Stricklandd
BRD | Director/Board Member | 48 | 01-01-17 |
Ana Gois
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Stricklandd
BRD | Director/Board Member | 48 | 01-01-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-0,09% | 42,12 mld. | |
+49,62% | 42,05 mld. | |
-4,96% | 29,18 mld. | |
+11,18% | 26,02 mld. | |
-21,95% | 18,9 mld. | |
+8,61% | 13,21 mld. | |
+24,73% | 12,17 mld. | |
+28,31% | 12,16 mld. | |
-6,26% | 11,42 mld. |